Liontrust Investment Partners LLP Has $37.30 Million Stock Holdings in TransMedics Group, Inc. $TMDX

Key Points

• Liontrust Investment Partners LLP reduced its stake in TransMedics Group, Inc. by 7.0%, selling 42,044 shares, and currently owns 1.64% of the company valued at approximately $37.3 million.
• TransMedics Group reported earnings of $0.92 per share for the last quarter, exceeding expectations of $0.48, with revenue of $157.37 million, up 37.7% year-over-year.
• The stock has received a consensus rating of "Moderate Buy" from analysts, with target prices ranging from $130.00 to $150.00.

Liontrust Investment Partners LLP trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 7.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 554,357 shares of the company's stock after selling 42,044 shares during the quarter. Liontrust Investment Partners LLP owned about 1.64% of TransMedics Group worth $37,297,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMDX. Sit Investment Associates Inc. increased its holdings in shares of TransMedics Group by 8.8% during the 1st quarter. Sit Investment Associates Inc. now owns 7,380 shares of the company's stock valued at $497,000 after acquiring an additional 600 shares during the last quarter. Montanaro Asset Management Ltd boosted its position in TransMedics Group by 9.7% during the first quarter. Montanaro Asset Management Ltd now owns 153,675 shares of the company's stock worth $10,339,000 after purchasing an additional 13,640 shares during the period. HighTower Advisors LLC boosted its position in TransMedics Group by 137.7% during the first quarter. HighTower Advisors LLC now owns 18,257 shares of the company's stock worth $1,228,000 after purchasing an additional 10,575 shares during the period. Trillium Asset Management LLC grew its holdings in TransMedics Group by 7.4% during the first quarter. Trillium Asset Management LLC now owns 35,389 shares of the company's stock valued at $2,381,000 after purchasing an additional 2,442 shares during the last quarter. Finally, Public Sector Pension Investment Board raised its position in shares of TransMedics Group by 27.4% in the first quarter. Public Sector Pension Investment Board now owns 106,480 shares of the company's stock valued at $7,164,000 after purchasing an additional 22,894 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX traded down $0.80 during trading hours on Wednesday, reaching $121.88. The stock had a trading volume of 834,118 shares, compared to its average volume of 1,270,411. The business's fifty day moving average is $122.60 and its two-hundred day moving average is $100.65. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The company has a market cap of $4.15 billion, a price-to-earnings ratio of 63.15 and a beta of 2.09. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business's revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. As a group, research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on TMDX shares. Morgan Stanley upped their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Canaccord Genuity Group upped their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Finally, Piper Sandler reissued an "overweight" rating and set a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $123.00.

Insider Activity

In other TransMedics Group news, Director David Weill sold 732 shares of TransMedics Group stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director directly owned 12,134 shares of the company's stock, valued at approximately $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward M. Basile sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total value of $632,250.00. Following the completion of the sale, the director owned 2,866 shares in the company, valued at approximately $362,405.70. This represents a 63.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,418 shares of company stock worth $818,833. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.